This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Settlement Amounts Approved In Australian DePuy Litigation Suggest U.S. Settlements Approaching; RD Legal Funding Supports DePuy Attorneys With Post-Settlement Financing

CRESSKILL, N.J., Dec. 12, 2012 /PRNewswire/ -- Settlement amounts have been approved for the DePuy Hip Implant litigants in Australia, fueling hopes that U.S. settlements are nearing. The Australian National Joint Replacement Registry, which began reporting problems to DePuy in 2007, led the fight to have the devices removed from the market. Without a U.S. joint replacement registry, American patients relied on their doctors' advice. But DePuy was indicted in 2007 for paying doctors kickbacks to recommend their devices, 37,000 of which they implanted in U.S. patients. More than 8,000 DePuy lawsuits remain to be settled in the U.S.; however payout could be months or years away. To ease the DePuy attorneys' financial burdens, lawsuit financing is available at RD Legal Funding once settlement amounts are finalized.

  • In 2005, the FDA approved DePuy's ASR™ XL Acetabular total hip replacement system without clinical trials because it resembled devices already on the market. Testing was required for DePuy's ASR™ hip resurfacing system, but DePuy dropped its request for approval when problems were revealed. Even without FDA approval, DePuy recommended the hip resurfacing system to U.S. doctors and continued selling it outside the U.S.
  • In September 2007, DePuy and three other companies paid $311 million in fines—without admitting any wrongdoing—to resolve U.S. Department of Justice allegations that they paid physicians kickbacks to use their artificial hip and knee products. The settlement agreement allowed the companies to enter into product development agreements with doctors, compensating them with royalties based on future sales, paid on an hourly basis with a cap of $500 an hour. In 2009, DePuy paid nearly $48 million to doctors; through September 2010, nearly $33 million.
  • Between 2007 and 2009, the Australian National Joint Replacement Registry warned DePuy 17 times about ASR problems, including a revision rate twice the normal expectancy rate of 15 years. Orthopedists questioning DePuy were told that their surgical techniques were at fault. DePuy device problems were reported at the 2007 Annual Fall Meeting of the American Association of Hip and Knee Surgeons and the 2008 British Orthopedic Association Conference.
  • DePuy voluntarily removed the ASR from the Australian market in late 2009, citing decreased demand, but left it on the market in other countries.
  • In August 2010, DePuy voluntarily recalled more than 93,000 ASR devices worldwide while maintaining that DePuy devices were performing at the same rates as similar devices.
  • In March 2011, the British Hip Society and British Orthopedic Association reported that revision rates for the ASR at four years were 21%; after six years, 49%.
  • With funding from orthopedists, prosthetic manufacturers, insurance companies, and hospitals, the American Joint Replacement Registry was founded in 2011 to track the 700,000 total hip and knee replacements performed each year in the U.S.
  • BMO Capital Markets reported that the worldwide hip replacement market would increase from $5.28 billion in 2010 by 3.2 percent in 2011.
  • In September 2012, the Australian National Joint Registry reported that DePuy ASR Hip Implants had a 44% revision rate at seven years as opposed to the 6% revision rate at ten years of all other total hip replacement devices.

For more information about post-settlement financing, attorneys for the DePuy litigants should contact RD Legal Funding at 1-800-565-5177 or go to Founded in 1997, RD Legal Funding is one of the nation's leading providers of post-settlement lawsuit funding to attorneys and plaintiffs.


1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs